Comparable stake leader
Stonepine Capital Management, LLC
SEC ownership of CNS Pharmaceuticals, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001729427.
Disclosed value leader
Stonepine Capital Management, LLC
Comparable rows
12/27
Latest evidence
18 May 2026
- Public ticker
- CNSP on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Stonepine Capital Management, LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
12 of 27
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Stonepine Capital Management, LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
18 May 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001729427
- Issuer location
- Houston, TX
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of CNS Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Stonepine Capital Managem...
Disclosed value leader
Stonepine Capital Managem...
Comparable rows
12/27
Latest evidence
18 May 2026
13D/G
13F
3/4/5
Lead comparable stake: 9.9%
15 rows are not safely comparable across share classes.
13D/G row: Stonepine Capital Management, LLC
Showing 1-8 of 27 holder rows.
Quick read
Stonepine Capital Management, LLC leads the comparable SEC ownership view at 9.9%.
12 of 27 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Stonepine Capital Management, LLC's linked filing trail.
Comparable ownership
Top 5
Stonepine Capital Management, LLC
9.9%
Ikarian Capital, LLC
5.7%
ARMISTICE CAPITAL, LLC
5%
GEODE CAPITAL MANAGEMENT, LLC
1.4%
BOOTHBAY FUND MANAGEMENT, LLC
0.84%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 27 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Stonepine Capital Management, LLC |
13D/G
13F
Company
|
9.9%
|
$402,671
159,790 shares
|
+$279,627 | 31 Mar 2026 |
| Ikarian Capital, LLC |
13D/G
13F
Company
|
5.7%
|
$118,700
45,830 shares
|
$0 | 31 Dec 2025 |
| ARMISTICE CAPITAL, LLC |
13D/G
|
5%
|
$5,432
30,177 shares
|
-$95,575 | 30 Sep 2025 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
1.4%
|
$55,653
23,189 shares
|
— | 31 Mar 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
Company
|
0.84%
|
$32,322
13,524 shares
|
— | 31 Mar 2026 |
| Tower Research Capital LLC (TRC) |
13F
Company
|
0.08%
|
$3,131
1,310 shares
|
— | 31 Mar 2026 |
| UBS Group AG |
13F
Company
|
0.05%
|
$1,742
729 shares
|
— | 31 Mar 2026 |
| BARRETT & COMPANY, INC. |
13F
Company
|
0%
|
$19
8 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$34,002.
Buys
$34,002
Insiders: 1
Sells
$0
Insiders: 0
Net
+$34,002
Shares: +7,100
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 7,100
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 7,100 | 0 | $34,002 | $0 | +$34,002 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-14 of 14 reporting-owner rows connected to CNS Pharmaceuticals, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
14
Largest Forms 3/4/5 holder
Waldemar Priebe
Net 12M change
+$34,002
Latest report
18 May 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Waldemar Priebe | 10%+ Owner | $198,486 | Mixed | 06 Dec 2022 | ||
| Cortice Biosciences, Inc. | 10%+ Owner | $172,010 | Mixed | 30 Jul 2024 | ||
| Carl Anthony Evans | Director | $54,165 | Mixed | 08 Apr 2024 | ||
| Faith L. Charles | Director | $34,001 | +$34,002 | +100% | Filing P/S | 18 May 2026 |
| Jerzy Gumulka | Director | Mixed | 17 Nov 2025 | |||
| Andrzej Andraczke | Director | Mixed | 21 Sep 2023 | |||
| Christopher Downs | Chief Financial Officer | Mixed | 17 Nov 2025 | |||
| Rami Levin | CEO and President, Director | Mixed | 01 Jan 2026 | |||
| Steve O'Loughlin | Chief Financial Officer | Mixed | 02 Mar 2026 | |||
| Amy Mahery | Director | Mixed | 17 Nov 2025 | |||
| Eric Faulkner | Chief Technology Officer | Mixed | 02 Mar 2026 | |||
| Bettina M. Cockroft | Director | Mixed | 17 Nov 2025 | |||
| John M. Climaco | Chief Executive Officer, Director | Mixed | 17 Nov 2025 | |||
| Jeffry R. Keyes | Director | Mixed | 17 Nov 2025 |
Recent insider transactions for CNS Pharmaceuticals, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Faith L. Charles | CNSP | Common Stock | Purchase | $34,002 | $4.79 | 7,100 | 7,100 | 18 May 2026 | Direct | |
| Eric Faulkner | CNSP | Restricted Stock Units | Award | 9,500 | 9,500 | 02 Mar 2026 | Direct | |||
| Steve O'Loughlin | CNSP | Restricted Stock Units | Award | 9,500 | 9,500 | 02 Mar 2026 | Direct | |||
| Rami Levin | CNSP | Restricted Stock Units | Award | 19,000 | 19,000 | 01 Jan 2026 | Direct | |||
| Jeffry R. Keyes | CNSP | Option to purchase common stock | Award | 1,517 | 1,517 | 17 Nov 2025 | Direct | |||
| Bettina M. Cockroft | CNSP | Option to purchase common stock | Award | 1,517 | 1,517 | 17 Nov 2025 | Direct | |||
| John M. Climaco | CNSP | Option to purchase common stock | Award | 9,761 | 9,761 | 17 Nov 2025 | Direct | |||
| Amy Mahery | CNSP | Option to purchase common stock | Award | 1,517 | 1,517 | 17 Nov 2025 | Direct | |||
| Faith L. Charles | CNSP | Option to purchase common stock | Award | 1,517 | 1,517 | 17 Nov 2025 | Direct | |||
| Christopher Downs | CNSP | Option to purchase common stock | Award | 4,881 | 4,881 | 17 Nov 2025 | Direct | |||
| Jerzy Gumulka | CNSP | Option to purchase common stock | Award | 1,517 | 1,517 | 17 Nov 2025 | Direct |
* marks a reported price that did not pass the local price check.